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Objectives The purpose of this study was to determine whether obese individuals with reduced adipose tissue inflammation
exhibit a more favorable cardiovascular risk profile.
Background Obesity is associated with a low-grade state of chronic inflammation that might be causally related to cardio-
metabolic disease.
Methods With immunohistochemistry, we categorized obese individuals dichotomously as having inflamed fat (n  78) or
noninflamed fat (n  31) on the basis of the presence () or absence () of macrophage crown-like structures
(CLS) in subcutaneous abdominal fat biopsy samples. We compared their metabolic, vascular, and adipose tis-
sue characteristics with lean subjects (n  17).
Results Inflamed CLS obese individuals displayed higher plasma insulin, homeostasis model assessment, triglycerides,
glucose, blood pressure, high-sensitivity C-reactive protein, low-density lipoprotein cholesterol, lower high-density
lipoprotein cholesterol, and brachial artery flow-mediated dilation compared with lean subjects (p  0.05). Adipose
messenger ribonucleic acid expression of inflammatory genes including CD68, leptin, matrix metalloproteinase-9,
CD163, and CD8A were significantly greater and vascular endothelial growth factor was lower in the CLS group
(p  0.05). In contrast, obese subjects with noninflamed fat exhibited a mixed clinical phenotype with lower insulin
resistance, reduced proatherogenic gene expression, and preserved vascular function as in lean subjects. In multiple
linear regression adjusting for age and sex, CLS status (beta  0.28, p  0.008) and waist circumference (beta 
0.25, p  0.03) were independent predictors of flow-mediated dilation.
Conclusions These findings lend support to the novel concept that factors in addition to absolute weight burden, such as
qualitative features of adipose tissue, might be important determinants of cardiovascular disease. Therapeutic
modulation of the adipose phenotype might represent a target for treatment in obesity. (J Am Coll Cardiol
2011;58:232–7) © 2011 by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.01.051There is growing recognition that many overweight indi-
viduals maintain a relatively favorable cardiometabolic pro-
file even in extreme obesity. Determinants of a metabolically
healthier obese phenotype are poorly understood and likely
multifactorial, relating to differences in body fat distribu-
tion, physical activity, and adipose metabolism (1). In
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22, 2010, accepted January 18, 2011.addition, recent data suggest that inflammation of adipose
tissue orchestrated by monocyte/macrophage infiltration
and overproduction of proatherogenic cytokines might me-
diate metabolic and vascular disease in human obesity (2,3).
Chronic activation of the immune system has been strongly
implicated in the pathogenesis of obesity-associated disor-
ders, including type 2 diabetes mellitus, cancer, and cardio-
vascular disease, and is a growing target of interest for
therapeutic intervention (4).
See page 256
We and others have previously shown that pro-
inflammatory changes in fat are linked to metabolic stress
and endothelial dysfunction (2,5,6). The goals of the pres-
ent study were to determine whether qualitative differences
exist between the adipose tissue of obese versus normal
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patients with reduced adipose inflammation are polarized
toward a lean phenotype.
Methods
Study subjects. We enrolled overweight adult men and
women (18 years of age) with a body mass index (BMI) of
25 kg/m2 receiving care at the Boston Medical Center. We
also recruited lean adults (BMI 25 kg/m2) through adver-
tisements to the general public. Subjects with unstable medical
conditions or pregnancy were excluded. The study was ap-
proved by Boston Medical Center Institutional Review
Board, and all subjects gave written informed consent.
Blood pressure, heart rate, height, weight, BMI, and waist
circumference (WC) were recorded for each subject, and all
biochemical analyses were quantified from fasting blood
samples.
Subcutaneous adipose tissue collection. From each sub-
ject, we collected abdominal subcutaneous adipose tissue via
percutaneous needle biopsy technique or directly harvested
during gastric bypass surgery, as previously described (2,7).
All subjects were in a fasting state for 12 h before biopsy.
Each subject provided a single biopsy specimen from the
subcutaneous region for analysis.
Adipose tissue histology and real-time polymerase chain
reaction. Macrophages in adipose tissue were identified
with cell-specific stains targeted to CD68 (DakoCytoma-
tion, Carpinteria, California). Obese subjects were dichot-
omously categorized, on the basis of the presence () or
absence () of macrophage crown-like structures (CLS), as
CLS if any adipose tissue macrophage clusters were
present in any examined field (inflamed fat) or CLS if
clusters were absent (non-inflamed fat) as previously vali-
dated (2,8,9). All lean subjects were CLS. For messenger
ribonucleic acid (mRNA) expression analyses, samples were
homogenized with a MagNa Lyser tissue homogenizer
(Roche Applied Science, Indianapolis, Indiana). Quantita-
tive real-time polymerase chain reactions were performed
with a high-throughput instrument (BioMark, Fluidigm,
San Francisco, California) with Gene Expression Assays
(Applied Biosystems, Foster City, California) and Dynami-
cArray chips (Fluidigm, San Francisco, California) (10).
Vascular studies. For each subject, brachial artery ultra-
sound studies were performed in a fasting state. Brachial
vasomotor responses were examined with a noninvasive,
standardized method of ultrasound with a Toshiba Pow-
ervision 6000 system (Toshiba, Tokyo, Japan), as previously
described (2,11). Flow-mediated dilation (FMD) after a
5-min cuff occlusion in an upper arm position and
nitroglycerin-mediated dilation of the brachial artery served
as measures of endothelium-dependent and -independent
dilation, respectively. Sublingual nitroglycerin (0.4 mg) was
omitted if contraindicated or the subject declined.
Statistical analysis. Analyses were completed with SAS for
Windows (version 9.1, SAS Institute, Inc., Cary, NorthCarolina). Data are presented as
mean  SD, median with inter-
quartile range, or proportions
(%). Categorical group differ-
ences were examined with the
chi-square test or Fisher exact
test as appropriate. Kolgomorov-
Smirnov tests, histograms, and
normal probability plots were
used to determine whether con-
tinuous variables were normally
distributed or skewed. Natural
log transformation was applied
only to continuous variables not
meeting normality, which specif-
ically were glucose, homeostasis
model assessment (HOMA), in-
sulin, triglycerides, as well as ad-
ipose expression of interleukin
(IL)-8, catalase, peroxiredoxin-1,
guanylate cyclase I alpha/beta,
IL-6, and IL-1beta. The latter 4 genes did not reach
normality despite transformation and were analyzed by
nonparametric methods. Group differences for continuous
variables were examined with analysis of variance with
Tukey post-hoc analysis, and the Kruskal-Wallis test was
used for skewed variables. Univariate associations between
vascular parameters or HOMA and clinical data were
examined in obese subjects with Pearson’s correlation.
Alternatively, Spearman’s rank correlation was used for
skewed data. Multiple linear regression was used to deter-
mine whether CLS status was independently associated
with FMD. Univariate clinical correlates of FMD with
significance level of p 0.1 were included in the model. For
all analyses, p value 0.05 was considered statistically
significant.
Results
Clinical and histological data. A total of 109 obese
subjects (mean age 42  11 years, 86% women) and 17 lean
individuals (mean age 33  12 years, 77% women) com-
pleted this study. The clinical characteristics of all partici-
pants are displayed in Table 1. The majority of obese
individuals (72%) demonstrated evidence of adipose inflam-
mation characterized by tissue presence of macrophage
crown-like structures in subcutaneous fat (CLS, n  78)
as shown in Figure 1, which were absent in 28% of
overweight subjects (CLS, n  31). In contrast, all lean
subjects were noninflamed (CLS). As expected, the lean
group had significantly lower BMI, WC, plasma insulin,
HOMA, LDL-C, glycosylated hemoglobin A1C (HbA1c),
triglycerides, glucose, hs-CRP, hypertension, diabetes prev-
alence, medication use, and higher HDL-C levels compared
with the CLS obese group (p  0.05). However, despite
Abbreviations
and Acronyms
BMI  body mass index
CLS  crown-like
structures
FMD  flow-mediated
dilation
HbA1C  glycosylated
hemoglobin A1C
HOMA  homeostasis
model assessment
hs-CRP  high-sensitivity
C-reactive protein
IL  interleukin
MMP  matrix
metalloproteinase
mRNA  messenger
ribonucleic acid
WC  waist circumferencethe same degree of adiposity, sex distribution, and age range
pl
C
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significantly lower in CLS obese, exhibiting values that
were intermediate to the lean and inflamed overweight
groups (p  0.05).
Vascular parameters. Vascular function data for all 3
groups are displayed in Table 2. Brachial artery FMD (n 
126) was significantly impaired in the CLS subjects
compared with both lean and CLS groups, demonstrating
that subjects with reduced adipose inflammation display
endothelium-dependent vasodilation similar to those with
normal weight. In contrast, endothelium-independent
Clinical CharacteristicsTable 1 Clinical Characteristics
Lean
(n  17)
Obese
(CLS)
(n  31)
Obese Inflamed
(CLS)
(n  78)
Age (yrs) 33 12 40 10 43 12*
Female (%) 77 97 82
BMI (kg/m2) 22 1 45 7* 45 9*
Waist circumference (cm) 76 1 127 6* 130 7*
Weight (kg) 63 7 118 20* 127 29*
Insulin (uIU/ml) 2,1 10.5,7* 14,12*†
HOMA 0.5,0.2 2.3,1.7* 4.1,3.4*†
Triglycerides (mg/dl) 62,34 83,43* 107,89*
Glucose (mg/dl) 86,10 92,21* 100,26*
HDL-C (mg/dl) 67 18 49 9* 49 14*
LDL-C (mg/dl) 97 24 115 26* 121 31*
Total cholesterol (mg/dl) 178 29 183 29 194 36
HbA1c (%) 5.3 0.3 6.1 1.0* 6.3 1.1*
hs-CRP (mg/dl) 0.9 0.9 5.1 3.9* 8.5 9.5*
Diabetes (%) 0 26* 36*
Hypertension (%) 0 36* 46*
Hypoglycemic use (%) 0 13 32*
Lipid-lowering use (%) 0 13 26*
Active smoker (%) 0 16 8
Values are mean  SD or median, interquartile range. *p  0.05 versus lean; †p  0.05 versus
crown-like structures (CLS) obese.
BMI  body mass index; HbA1C  glycosylated hemoglobin A1C; HDL-C  high-density
ipoprotein cholesterol; HOMA  homeostasis model assessment; hs-CRP  high-sensitivity
-reactive protein; LDL-C  low-density lipoprotein cholesterol.
Figure 1 Representative Histology of Inflamed Human Subcuta
The CD68 macrophages (brown color) are organized into multiple “crown-like st
of chronic local inflammation in human fat tissue. (A) 20 power; (B) 40 powernitroglycerin-mediated dilation (n  67) was significantly
reduced in obese groups compared with the lean subjects
(p  0.05). As shown in Table 3, univariate correlates of
brachial artery FMD in obese subjects were WC,
HOMA, HbA1c, and adipose IL-6 and chemokine C-C
motif ligand 2 expression. The HOMA correlated posi-
tively with WC, BMI, HbA1c, triglycerides, plasma
hs-CRP, and adipose IL-1beta expression and negatively
with HDL-C and FMD. In multiple linear regression
with adjustment for age, sex, and HOMA, CLS status
(CLS vs. CLS; beta   0.28, p  0.008) and WC
(beta  0.25, p  0.03) were the only significant
redictors of FMD (model R2  0.19).
Adipose tissue gene expression. We identified specific
genes that were differentially expressed between subcutane-
ous adipose tissue of all 3 groups. As shown in Figures 2A
to 2E, CD68, leptin, matrix metalloproteinase (MMP)-9,
CD163 (M2 macrophage marker), and CD8A mRNA
expression were greatest in the CLS obese group and
lowest in lean subjects, with intermediate values in CLS
subjects (p  0.05 for all inter-group differences). Lean
individuals also exhibited significantly lower mRNA expres-
sion of IL-8 (neutrophil chemotaxis), chemokine C-C
motif ligand 2, IL-6, TNF-alpha, IL-1beta, and MRC1
(M2 marker, CD 206 mannose receptor) and higher expres-
sion of vascular endothelial growth factor-A (Fig. 2F),
compared with both obese groups (p  0.05). Increased
oxidative stress has been implicated in mechanisms of
obesity-related metabolic disorders (12). In this regard, we
observed decreased expression of antioxidant enzymes cat-
alase, superoxide dismutase, and peroxiredoxin-1 and mark-
ers of local nitric oxide bioavailability (endothelial nitric
oxide synthase and guanylate cyclase I alpha/beta) in the
adipose tissue of obese as compared with lean subjects (p 
0.05). Conversely, we observed increased expression of
pro-oxidant enzymes, including nicotinamide adenine dinu-
cleotide phosphate oxidase cytochrome b (p  0.01) and
Adipose Tissue as Demonstrated With Light Microscopy
s” that encircle necrotic adipocytes as a hallmark
arrows  macrophages, dotted arrow  adipocyte.neous
ructure
. Solid
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(p  0.06), in the adipose tissue of obese subjects. The
findings support a milieu of increased oxidative stress in
association with obesity; however, our measured tissue
variables did not specifically correlate with systemic vascular
responses.
Discussion
In the present study, we demonstrate that obese individuals
display more pro-atherogenic vascular, metabolic, and adi-
pose tissue profiles as compared with lean subjects. The key
finding was that, for the same degree of severe obesity,
individuals with reduced adipose inflammation exhibited an
“intermediate” clinical phenotype with arterial function
similar to normal weight subjects. We observed parallel
trends in adipocytokine expression that mirrored systemic
profiles, suggesting a biological connection. In this regard,
the findings prompt speculation that aspects of cardiovas-
cular disease mechanisms might have origins within the
adipose microenvironment.
Animal models consistently show that excess adiposity
induces a chronic state of immune system activation, char-
acterized by adipose tissue influx of macrophages, neutro-
phils, and T lymphocytes that stimulate adipocytokine
production implicated in the temporal development of
insulin resistance (13). We now recognize that the conse-
Vascular DataTable 2 Vascular Data
Lean
Obese
(CLS)
Obese Inflamed
(CLS)
Systolic BP (mm Hg) 117 11 129 14* 130 16*
Diastolic BP (mm Hg) 67 6 75 9* 73 10*
Brachial diameter (mm) 3.4 0.7 3.8 0.5 4.2 0.7*†
FMD (%) 12.5 6 12.4 4 9.2 4*†
NMD (%) 22.4 10 15.2 5* 13.2 6*
*p  0.05 versus lean; †p  0.05 versus crown-like structures (CLS) obese.
BP  blood pressure; FMD  flow-mediated dilation; NMD  nitroglycerin-mediated dilation.
Clinical CorrelationsTable 3 Clinical Correlations
Coefficient p Value
Correlates of FMD
Waist circumference 0.26 0.01
HOMA 0.20 0.05
HbA1c 0.26 0.001
CCL2 0.25 0.01
IL-6 0.25 0.02
Correlates of HOMA
Waist circumference 0.43 0.001
BMI 0.36 0.001
HbA1c 0.42 0.001
Triglycerides 0.57 0.001
hs-CRP 0.26 0.02
IL-1beta 0.23 0.03
HDL-C 0.33 0.001CCL2  chemokine C-C motif ligand 2; IL  interleukin; other abbreviations as in Tables 1 and 2.quence of adipose inflammation likely extends beyond
metabolic disturbance to cause vascular injury and athero-
sclerosis. For example, adipose tissue inflammation induces
endothelial activation and alters blood flow in the microcir-
culation of obese mice (14). Inflamed perivascular fat
preferentially localizes to atherosclerotic regions, and adi-
pocytokines impair vasomotor function (15). These findings
show that functional properties of blood vessels are ad-
versely modulated by the state of the adipose microenviron-
ment. Thus, it is plausible to speculate that disease at the
adipose level might extend and reflect in the systemic
vasculature, because this concept is supported by our finding
that obese patients with reduced adipose inflammation
displayed favorable arterial responses as in lean subjects.
This might hold clinical significance, because prospective
studies consistently show that endothelial dysfunction pre-
dicts cardiovascular events (16).
The degree of adipose immune activation in humans is
more variable than in genetically modified experimental
animals, and this heterogeneity in tissue phenotype provides
Figure 2 Adipose Tissue Messenger
Ribonucleic Acid Gene Expression
Lean and obese individuals are stratified by crown-like structures (CLS) status
for (A) CD68; (B) matrix metalloproteinase (MMP)-9; (C) leptin; (D) CD163;
(E) CD8A; and (F) vascular endothelial growth factor (VEGF)-A. *p  0.05
versus lean; †p  0.05 versus CLS obese.
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relate to clinical disease. In this regard, we demonstrated
that a specific pattern of macrophage build-up in fat is
associated with metabolic and endothelial dysfunction (2,7).
The key issue of what sets off the inflammatory cascade in
fat is not well-understood and likely multifactorial, relating
to adipocyte hypertrophy and dysfunction, oxidative stress,
toxic lipolysis, and deficient neovascular remodeling (17).
Adipose activation and adipocytokine overproduction might
have systemic consequences. For example, we demonstrated
over-expression of MMP-9, which plays a key role in matrix
turnover and remodeling as part of the activated tissue
profile. Plasma metalloproteinase concentrations are in-
creased in obese subjects and clinical studies show that fat is
a significant source (5). Because MMP-9 destabilizes ath-
erosclerotic plaques, consequences of weight gain might be
germane to cardiovascular risk (18).
Adipose tissue macrophages largely originate from circu-
lating monocytes (13). They can exist in at least 2 differen-
tially activated states characterized as M1 macrophages that
produce pro-inflammatory cytokines linked to insulin resis-
tance and atherosclerosis and alternative M2 phenotypes
involved in immunosuppressive functions (19). In obese
animals, these cell lines show predominantly M1 character-
istics (20), whereas human fat displays mixed phenotypes
(5). Their precise role in human disease is unknown, and
whether macrophage polarization influences the pathogenic
profile of fat remains an open question (5). Most probably,
immune changes in humans are dynamic, with activation of
pro-inflammatory “danger signals” in early phases of weight
gain followed by adaptive remodeling, because the expres-
sion for many acute phase cytokines was similar in both
obese groups. We demonstrated increased expression for
M2 markers of CD163 and CD206, suggesting that com-
pensatory immunosuppressive pathways might be triggered
in later stages of obesity.
Our seminal finding was that obese individuals without
pro-inflammatory adipose changes displayed more favorable
clinical characteristics. This subset represented approxi-
mately 30% of our obese cohort, strikingly similar in
proportion to metabolically healthier obese phenotypes in
large population studies (21). Both WC and the presence of
CLS in adipose tissue were independent predictors of
brachial artery FMD, suggesting that both “quantity” and
“quality” of fat might be germane to systemic disease (22).
Study limitations. To minimize subject discomfort, we
relied on a single subcutaneous biopsy site for adipose tissue
characterization; therefore, it remains possible that some
individuals were miscategorized owing to sampling error.
Our analyses were limited to subcutaneous fat, which was
readily accessible. Because visceral depots are felt to be more
metabolically active and pathogenic in nature, it is possible
that stronger correlations could have been observed (23,24).
Most participants in the present study were women, reflect-
ing general clinical practice and sex differences in popula-
tions that seek weight loss treatments (25). Macronutrientintake plays an important role in adaptive immune re-
sponses. Although we did not specifically record daily food
logs, we acknowledge that chronic differences in dietary
patterns could influence metabolic states (26,27). These
limitations are counterbalanced by the relatively large sam-
ple size for this type of invasive clinical study and novel
translational information generated in severe human obesity
where limited information currently exists.
Conclusions
We identified a group of obese subjects with reduced
adipose inflammation that exhibit intermediate risk factor
profiles. We hypothesize that individuals prone to inflam-
matory activation with weight gain might have increased
cardiometabolic risk. Therapeutic modulation of the adi-
pose phenotype might represent a novel target for treatment
in obesity.
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